The Severe Acute Respiratory Syndrome-related Coronavirus 2 (SARS-CoV-2)-driven coronavirus disease 2019 (COVID-19) pandemic has fundamentally changed our world, country, community and families. In patients who die of COVID-19, activation of evolutionarily-conserved inflammatory cascades results in massive increases in circulating levels of inflammatory cytokines producing vascular leak, edema of multiple critical organ (lung, kidneys, heart, brain, liver, GI tract), ultimately leading to multi-organ dysfunction including acute respiratory distress syndrome (ARDS). There is lack of deep understanding regarding the risk factors for and biology of COVID-19. The pandemic has also dramatically highlighted the multiple unmet needs in the care for patients with SARS-CoV-2 infection including the lack of validated biomarkers, and of effective FDA?approved pharmacotherapies. Accordingly, this Administrative Supplement seeks to further our understanding through immunophenotyping patients who develop COVID-19. We will provide clinical data and sample collection/processing from a cohort of SARS-CoV2 patients enrolled in Tucson, Arizona. The clinical data and samples will be transmitted to the central cores that are assigned by the Immunophenotyping Assessment in a COVID-19 Cohort (IMPACC) study with the overarching objectives to better understand the pathogenesis of COVID-19 disease and to identify immunological pathways that can be used to inform us on how to combat this disease.
In Specific Aim 1, we will recruit and provide clinical data (demographics, clinical laboratory test results and imaging results, clinical course) longitudinally from patients hospitalized with COVID- 19 infection to the designated IMPACC cores in order to establish correlation with immune status and disease progression.
In Specific Aim 2, we will provide biological specimens (serum, whole blood, PBMCs, nasopharyngeal samples, endotracheal aspirates) from patients hospitalized with COVID-19 infection to the designated cores in order to characterize the immunophenotypes and the immune status and response to infection. This supplement supports the University of Arizona's participation in IMPACC to facilitate screening and enrollment of inpatients with COVID-19. The proposed supplement research is within the scope of parent U19 grant entitled ?Dysfunction of Innate Immunity in Asthma? (1U19AI125357). In summary, the IMPACC study coordinates a national, multi-institution consortium, collecting detailed clinical data and biologic samples from hospitalized COVID-19 infected individuals, with the goal of identifying immune signatures/molecular biomarkers associated with clinical disease course. These data will allow the prioritization of clinical interventions and therapeutic decision making.

Public Health Relevance

In less than six months, the COVID-19 infection has become a word-wide pandemic and fundamentally changed our world. There are major gaps in our knowledge of how to deal with this virus including the lack of effective therapy and an understanding of how different people react to infection by this virus. In this administrative supplement, we propose to establish a COVID-19 cohort and study the pathogenesis of the virus.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Program--Cooperative Agreements (U19)
Project #
Application #
Study Section
Program Officer
Minnicozzi, Michael
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Arizona
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Dakhama, Azzeddine; Chu, Hong Wei (2018) The Use of CRISPR-Cas9 Technology to Reveal Important Aspects of Human Airway Biology. Methods Mol Biol 1799:371-380
Ito, Yoko; Schaefer, Niccolette; Sanchez, Amelia et al. (2018) Toll-Interacting Protein, Tollip, Inhibits IL-13-Mediated Pulmonary Eosinophilic Inflammation in Mice. J Innate Immun 10:106-118
Ito, Yoko; Al Mubarak, Reem; Roberts, Nicole et al. (2018) IL-13 induces periostin and eotaxin expression in human primary alveolar epithelial cells: Comparison with paired airway epithelial cells. PLoS One 13:e0196256
Lugogo, Njira; Francisco, Dave; Addison, Kenneth J et al. (2018) Obese asthmatic patients have decreased surfactant protein A levels: Mechanisms and implications. J Allergy Clin Immunol 141:918-926.e3
Roberts, Nicole; Al Mubarak, Reem; Francisco, David et al. (2018) Comparison of paired human nasal and bronchial airway epithelial cell responses to rhinovirus infection and IL-13 treatment. Clin Transl Med 7:13
Kummarapurugu, Apparao B; Zheng, Shuo; Ledford, Julie et al. (2018) High-Mobility Group Box 1 Upregulates MUC5AC and MUC5B Expression in Primary Airway Epithelial Cells. Am J Respir Cell Mol Biol 58:126-128
Carr, Tara F; Kraft, Monica (2017) Management of Severe Asthma before Referral to the Severe Asthma Specialist. J Allergy Clin Immunol Pract 5:877-886
Jiang, Di; Matsuda, Jennifer; Berman, Reena et al. (2017) A novel mouse model of conditional IRAK-M deficiency in myeloid cells: application in lung Pseudomonas aeruginosa infection. Innate Immun 23:206-215
Noutsios, George T; Willis, Amanda L; Ledford, Julie G et al. (2017) Novel role of surfactant protein A in bacterial sinusitis. Int Forum Allergy Rhinol 7:897-903
Huang, C; Jiang, D; Francisco, D et al. (2016) Tollip SNP rs5743899 modulates human airway epithelial responses to rhinovirus infection. Clin Exp Allergy 46:1549-1563